Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

KalVista Pharmaceuticals (KALV) Non Operating Income (2016 - 2025)

KalVista Pharmaceuticals' Non Operating Income history spans 11 years, with the latest figure at -$1.2 million for Q2 2025.

  • On a quarterly basis, Non Operating Income fell 418.42% to -$1.2 million in Q2 2025 year-over-year; TTM through Apr 2025 was $2.3 million, a 72.88% decrease, with the full-year FY2025 number at $4.8 million, down 50.73% from a year prior.
  • Non Operating Income hit -$1.2 million in Q2 2025 for KalVista Pharmaceuticals, down from $2.1 million in the prior quarter.
  • Over the last five years, Non Operating Income for KALV hit a ceiling of $4.1 million in Q1 2024 and a floor of -$1.2 million in Q2 2025.
  • Historically, Non Operating Income has averaged $1.6 million across 4 years, with a median of $2.1 million in 2023.
  • Biggest five-year swings in Non Operating Income: increased 1.1% in 2024 and later plummeted 418.42% in 2025.
  • Tracing KALV's Non Operating Income over 4 years: stood at $2.2 million in 2021, then dropped by 3.45% to $2.1 million in 2023, then increased by 1.1% to $2.1 million in 2024, then plummeted by 155.78% to -$1.2 million in 2025.
  • Business Quant data shows Non Operating Income for KALV at -$1.2 million in Q2 2025, $2.1 million in Q4 2024, and $1.6 million in Q3 2024.